Perrigo (NYSE:PRGO) Updates FY 2025 Earnings Guidance

Key Points

• Perrigo has updated its FY 2025 earnings guidance, projecting EPS between 2.900-3.100, slightly below the consensus estimate of 3.042. It also forecasts revenues of $4.4 billion-$4.5 billion, aligning with consensus estimates.
• Wall Street Zen downgraded Perrigo from a "buy" to a "hold" rating, with four analysts rating the stock a "hold" and one a "buy," resulting in an average price target of $33.00.
• Perrigo's most recent quarterly earnings report indicated a miss in both EPS and revenue estimates, with a reported EPS of $0.57 compared to the consensus of $0.59.

Perrigo (NYSE:PRGO - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 2.900-3.100 for the period, compared to the consensus EPS estimate of 3.042. The company issued revenue guidance of $4.4 billion-$4.5 billion, compared to the consensus revenue estimate of $4.4 billion.

Analyst Ratings Changes

Separately, Wall Street Zen cut Perrigo from a "buy" rating to a "hold" rating in a research report on Saturday, July 26th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $33.00.

Perrigo Price Performance

Shares of PRGO stock traded down $0.79 on Thursday, reaching $22.83. The company's stock had a trading volume of 4,135,987 shares, compared to its average volume of 1,468,003. The company has a market capitalization of $3.14 billion, a price-to-earnings ratio of -17.42 and a beta of 0.47. The stock's fifty day simple moving average is $26.93 and its 200-day simple moving average is $26.35. The company has a current ratio of 2.36, a quick ratio of 1.28 and a debt-to-equity ratio of 0.82. Perrigo has a 1 year low of $21.03 and a 1 year high of $30.93.

Perrigo (NYSE:PRGO - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.57 earnings per share for the quarter, missing analysts' consensus estimates of $0.59 by ($0.02). The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.08 billion. Perrigo had a positive return on equity of 8.93% and a negative net margin of 4.16%. The business's quarterly revenue was down .9% on a year-over-year basis. During the same quarter last year, the firm earned $0.53 earnings per share. Analysts forecast that Perrigo will post 2.56 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 16th. Shareholders of record on Friday, August 29th will be given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a dividend yield of 5.1%. The ex-dividend date is Friday, August 29th. Perrigo's payout ratio is -88.55%.

Hedge Funds Weigh In On Perrigo

A number of institutional investors have recently modified their holdings of PRGO. Goldman Sachs Group Inc. raised its position in Perrigo by 126.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company's stock valued at $32,520,000 after purchasing an additional 647,982 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Perrigo by 6.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company's stock worth $14,388,000 after acquiring an additional 32,151 shares during the period. United Services Automobile Association purchased a new position in Perrigo during the 1st quarter valued at about $250,000. Geneos Wealth Management Inc. lifted its position in shares of Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company's stock worth $27,000 after purchasing an additional 786 shares during the period. Finally, Amundi increased its holdings in Perrigo by 11.7% during the first quarter. Amundi now owns 5,292 shares of the company's stock valued at $148,000 after buying an additional 556 shares during the period. 95.91% of the stock is owned by hedge funds and other institutional investors.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.